Abstract:

Covid 19 is an acute viral infection affecting the main respiratory system. Treatment practices were based on technical guidance from national health authorities, WHO, and CDC Atlanta. The study was aimed at enhancing the understanding of treatment practices for Covid 19. The study was based on a descriptive analysis of records of hundred patients in an urban health facility. 54% were females. 13% received vaccination of the first dose. 24% had known exposure; 39 had a history of co-morbidities. Disease severity was classified as ‘mild (59), moderate (28) and severe (12)’ 76 were managed at home through video-consultation. 42 (55%) were women. 91% treated at home recovered completely. 24 were hospitalized, and 8 of them were admitted in the Covid-19 Intensive care unit (ICU). 33% recovered completely among hospitalized. Covid 19 has affected all age groups, and the median age was 43.5. Elderly and high-risk patients were prone to severe disease. 76% had no history of exposure suggesting community transmission. The diagnosis was based on the clinical status of 6 patients and the rest through RT PCR. All severe patients needed hospitalization. 77% of hospitalized recovered completely. 6% died, indicating close monitoring. Clinical outcome was dependent on disease severity. Complete recovery is possible in the majority of patients (78%). Treatment practices varied from using simple supplements to use of steroids and to anti-viral. Colchicine was prescribed to two patients because of complications Isolation and diligent contact tracing, and timely management helped in containing the spread and effective management of Covid-19.

References:

[1] Centers for Disease Control and Prevention, February 2021, Clinical-guidance-management-patients, with confirmed Corona Virus Disease (COVD-19), https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html.

[2] Centers for Disease Control and Prevention, 2019, Therapeutic Options for Covid-19 Patients  | CDC https://www.cdc.gov/coronavirus/-ncov/hcp/therapeutic-options.html.

[3] Weiss A, Jellingsø M, Sommer MOA. Spatial and temporal dynamics of SARS-CoV-2 in Covid-19 patients: a systematic review and meta-analysis. EBio Medicine 2020; 58: 102916.

[4] Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of Covid-19: immunity, inflammation, and intervention. Nat Rev Immunol 2020; 20: 363–74.

[5] Sarkar Chandan, Mondal Milon, Torequl Islam Muhammad, Martorell Miquel, Docea Anca Oana, Maroyi Alfred, Sharifi-Rad, 2020, Potential Therapeutic Options for Covid-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, Volume 11. www.frontiersin.org/article/10.3389/fphar.2020.572870.

[6] Recovery Collaborative Group, 2020, Dexamethasone in hospitalized patients with Covid-19—preliminary report. N Engl J Med 2020; published online July 17.

[7] Jin YH, Zhan QY, Peng ZY, et al. 2020 Sep 4, Chemoprophylaxis, diagnosis, treatments, and discharge management of Covid-19: An evidence-based clinical practice guideline (updated version). Mil Med Res. 2020;7(1): 41. doi:10.1186/s40779-020-00270-8.

[8] Becker, R.C., 2020, Covid-19 treatment update: follow the scientific evidence, J Thromb Thrombolysis 50, 43–53. https://doi.org/10.1007/s11239-020-02120-9.

[9] Centers for Disease Control and Prevention, Jan 14, 2022, Clinical Care Quick Reference for Covid-19, https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care-quick-reference.html#print.

[10] Diana Laila Ramatillah,Suri, Isnaini, April 2021, Treatment profiles and clinical outcomes of Covid-19 patients at private hospital in Jakarta, Plos OnE, https://doi.org/10.1371/journal.pone.0250147.

[11] Lagier JC, Million M, Gautret P, et al. 2020, Outcomes of 3,737 Covid-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis. Travel Med Infect Dis.; 36:101791. doi: 10.1016/j.tmaid.2020.101791.

[12] Zhao Jing, Gao Hao-Yu, Feng Zi-Yi, Wu Qi-Jun, 2020, A Retrospective Analysis of the Clinical and Epidemiological Characteristics of Covid-19 Patients in Henan Provincial People’s Hospital, Zhengzhou, China, Frontiers in Medicine, Volume 7, www.frontiersin.org/article/10.3389/fmed.2020.00286.

[13] WHO Solidarity trial consortium. February 2021, Repurposed antiviral drugs for Covid-19— interim WHO Solidarity trial results. The New England journal of Medicine, Volume 384, No.6.

[14] Wang Y, Zhang D, Du G, et al. 2020, Remdesivir in adults with severe Covid-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020; 395: 1569–78.

[15] Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19—final report. N Engl J Med 2020; 383: 1813–26.

[16] Barnby young, Tong Yan, Yee Sin Leo, November 26, 2020, the place of remdesivir in Covid-19, Lancet Infectious diseases Published Online https://doi.org/10.1016/ S1473-3099(20)30911-7.

[17] Lagier JC, Million M, Gautret P, et al. 2020, Outcomes of 3,737 Covid-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis. Travel Med Infect Dis.; 36:101791. doi: 10.1016/j.tmaid.2020.101791.

[18] Manenti L, Maggiore U, Fiaccadori E, et al. February 2021Reduced mortality in Covid-19 patients treated with colchicine: Results from a retrospective, observational study. PLoS ONE;16(3): e0248276. Published 2021 Mar 24. doi: 10.1371/journal.pone.0248276.

[19] Zhang L, Peng Y, Zheng Q, Jiang L, Tang S, Chen P. January 2021Retrospective analysis of clinical characteristics and laboratory results of Covid-19 patients. European Journal of Inflammation. doi:10.1177/20587392211011919.

[20] Spinner CD, Gottlieb RL, Criner GJ, et al. 2020 Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate Covid-19: a randomized clinical trial. JAMA; 324: 1048–57.

[21] Recovery Collaborative Group., 2020; Effect of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med 2020; published online October 8. https://doi.org/10·1056/NEJMoa2022926.

[22] Recovery Collaborative Group. 2020; Lopinavir–ritonavir in patients admitted to hospital with Covid-19 (Recovery): a randomised, controlled, open-label, platform trial. Lancet 396: 1345–52.